-
公开(公告)号：US20190336574A1
公开(公告)日：2019-11-07
申请号：US16406837
申请日：2019-05-08
发明人： Yibin Kang , Yongna Xing , Liling Wan , Feng Guo
摘要： The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
-
公开(公告)号：US20190292548A1
公开(公告)日：2019-09-26
申请号：US16230098
申请日：2018-12-21
发明人： Yibin Kang , Guohong Hu
IPC分类号： C12N15/113 , A61K45/06 , A61K31/7105 , C12Q1/6886 , A61K31/337 , A61K31/704 , A61K31/00 , A61K31/713
摘要： The present invention relates generally to methods for identifying cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. Embodiments of the present invention provide an objective means of prognostication regarding the long-term outcome of an incident of cancer, breast cancer in particular. Therapeutic modalities include immunotherapy and anti-sense therapy. Prognosis is determined by measuring the number of copies of the metadherin gene in the patient's cells.
-
公开(公告)号：US20170189481A1
公开(公告)日：2017-07-06
申请号：US15321337
申请日：2015-06-25
发明人： Yibin Kang , Yongna Xing , Liling Wan , Feng Guo
IPC分类号： A61K38/17
CPC分类号： A61K38/1709 , A61K38/08 , A61K38/10 , A61P35/00 , C07K14/4748 , C07K14/82
摘要： The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
-
4.发明申请JAGGED1 AS A MARKER AND THERAPEUTIC TARGET FOR BREAST CANCER BONE METASTASIS 审中-公开JAGGED1作为乳腺癌骨转移的标记和治疗目标公开(公告)号：US20150329918A1
公开(公告)日：2015-11-19
申请号：US14815607
申请日：2015-07-31
发明人： Yibin Kang , Nilay Sethi
IPC分类号： C12Q1/68
CPC分类号： G01N33/6893 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
摘要： A method of treating Jagged1 induced bone metastasis is provided. A method of analyzing patients with tumors insensitive to RANK targeting treatments, but may respond to Jagged1 or Notch targeting therapies is provided. A method of treating patients with Jagged1 induced bone metastasis is provided. A method of predicting the therapeutic of treating a cancer patient with bone metastasis is provided. A kit for treating patients with Jagged1 induced bone metastasis is provided. A kit for predicting the therapeutic outcome of treating a cancer patient with bone metastasis using RANKL inhibitors is provided.
摘要翻译： 提供了治疗Jagged1诱导的骨转移的方法。 提供了一种分析对RANK靶向治疗不敏感的肿瘤患者的方法，但可以对Jagged1或Notch靶向治疗作出反应。 提供了一种治疗Jagged1诱导骨转移的患者的方法。 提供了一种预测用骨转移治疗癌症患者的治疗方法。 提供了一种用于治疗Jagged1诱导的骨转移患者的试剂盒。 提供了一种用于预测使用RANKL抑制剂治疗患有骨转移的癌症患者的治疗结果的试剂盒。
-
公开(公告)号：US12054475B2
公开(公告)日：2024-08-06
申请号：US18488924
申请日：2023-10-17
发明人： Mark Esposito , John Proudfoot , Yibin Kang , John Piwinski
IPC分类号： A61K31/4709 , A61K31/473 , A61K31/4738 , A61P35/00 , C07D215/227 , C07D215/50 , C07D401/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D471/14 , C07D491/048 , C07D498/04 , C07D513/04
CPC分类号： C07D401/12 , A61P35/00 , C07D215/50 , C07D413/12 , C07D417/12 , C07D471/04 , C07D491/048 , C07D498/04 , C07D513/04
摘要： Provided herein are novel heterocyclic compounds, for example, compounds of Formula (IV-C). Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases, retinoid pathway activation, and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH) or as a male contraceptive.
-
公开(公告)号：US20210379147A1
公开(公告)日：2021-12-09
申请号：US17285188
申请日：2019-10-15
发明人： Yibin Kang , Minhong Shen
摘要： Disclosed is a method of treating cancer, involving the administration of a therapeutically effective amount of an inhibitor of the epidermal growth factor receptor (EGFR) pathway and the integrin/focal adhesion kinase (FAK) pathway to a patient in need of such treatment, where the inhibitor comprises at least the first 94 amino acids of a Tinagl1 protein, any fragments with conservative substitution showing 90% or greater homology to amino acids 22-94 of a Tinagl1 protein, or a signaling peptide fused or attached to a fragment with conservative substitution showing 90% or greater homology to amino acids 22-94 of a Tinagl1 protein.
-
公开(公告)号：US10745701B2
公开(公告)日：2020-08-18
申请号：US16230098
申请日：2018-12-21
发明人： Yibin Kang , Guohong Hu
IPC分类号： C12N15/113 , A61K31/713 , C12Q1/6886 , A61K45/06 , A61K31/7105 , A61K31/337 , A61K31/704 , A61K31/00
摘要： The present invention relates generally to methods for identifying cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. Embodiments of the present invention provide an objective means of prognostication regarding the long-term outcome of an incident of cancer, breast cancer in particular. Therapeutic modalities include immunotherapy and anti-sense therapy. Prognosis is determined by measuring the number of copies of the metadherin gene in the patient's cells.
-
公开(公告)号：US10357539B2
公开(公告)日：2019-07-23
申请号：US15321337
申请日：2015-06-25
发明人： Yibin Kang , Yongna Xing , Liling Wan , Feng Guo
摘要： The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
-
公开(公告)号：US10202605B2
公开(公告)日：2019-02-12
申请号：US15901174
申请日：2018-02-21
发明人： Yibin Kang , Guohong Hu
IPC分类号： C07H21/02 , C07H21/04 , A61K31/70 , C12N15/113 , A61K31/00 , A61K31/7105 , C12Q1/6886 , A61K31/337 , A61K31/704 , A61K45/06 , A61K31/713 , C12N5/00
摘要： The present invention relates generally to methods for identifying cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. Embodiments of the present invention provide an objective means of prognostication regarding the long-term outcome of an incident of cancer, breast cancer in particular. Therapeutic modalities include immunotherapy and anti-sense therapy. Prognosis is determined by measuring the number of copies of the metadherin gene in the patient's cells.
-
公开(公告)号：US20180230472A1
公开(公告)日：2018-08-16
申请号：US15901174
申请日：2018-02-21
发明人： Yibin Kang , Guohong Hu
IPC分类号： C12N15/113 , A61K31/337 , A61K31/704 , A61K31/7105 , A61K31/713 , A61K45/06 , C12Q1/6886 , A61K31/00
CPC分类号： C12N15/1135 , A61K31/00 , A61K31/337 , A61K31/704 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N2310/11 , C12N2310/14 , C12N2320/30 , C12N2320/31 , C12Q1/6886 , C12Q2600/118 , C12Q2600/156
摘要： The present invention relates generally to methods for identifying cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. Embodiments of the present invention provide an objective means of prognostication regarding the long-term outcome of an incident of cancer, breast cancer in particular. Therapeutic modalities include immunotherapy and anti-sense therapy. Prognosis is determined by measuring the number of copies of the metadherin gene in the patient's cells.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.038 秒)
